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TOHYAMA circumstances, the Japanese Society for Laboratory Hematology (JSLH) was launched in March 2000 and has been developed by the leadership of the physician hematologists and medical technologists all of whom had a strong interest and needs for laboratory hematology and by a collaboration with the companies involved in hematological laboratory testing. Three important persons who contributed to the beginning of JSLH were as follows: Prof. Kiyoaki Watanabe at Keio University, Prof. Kazuhiko Nakahara at University of Tokyo, and Prof. Noriyuki Tatsumi at Osaka City University.
After launching of this new academy, JSLH has been steadily developed as shown in Figure 1 .
| AC TIVITIE S OF JS LH AND PROMOTION OF THE S TANDARD IZ ATI ON OF L ABOR ATORY HEMATOLOGY
The aim of JSLH is the progress and development of laboratory hematology. For this purpose, main projects are raised as follows:
• Academic conferences:annual meeting in summer, training seminar in winter and local meeting in 5 regions of Japan.
• Periodic publication of an official journal (in Japanese with English abstracts)
• Training or educational session in the annual and local meeting
• Promotion of the standardization of laboratory hematology
• Certification of the laboratory hematology specialists (eg, bone marrow evaluation)
The official journal, Journal of the JSLH, has been published for 18 years from the beginning of this society. One volume consists of 3 regular issues and 1 proceeding issue of the annual meeting.
Publication of the English abstract in PubMed is being discussed as a near future matter.
As for the standardization of laboratory hematology, 3 specialized committees are organized as follows and playing an active role one another:
• Standardization of blood cell counting by the use of automated hematology analyzers 1, 2 • Standardization of blood cell morphology
• Standardization of thrombosis and hemostasis
| S TANDARD IZ ATI ON OF B LOOD CELL MORPHOLOGY IN JAPAN
The standardization committee on blood cell morphology has been dealing with the various projects as follows:
• Methods for blood smear preparation "The forced-drying method of the fresh smear slides using a cold air drier" is widely accepted and practiced in Japan, unlike the natural-drying method generally carried out in Western countries.
By this method, most of the blood cells are well spread and beautifully stained by May-Grünwald-Giemsa or Wright-Giemsa staining method 
| AIMING AT THE S TANDARD IZ ATI ON OF E VALUATING DYS PL A S TI C MORPHOLOGY OF MDS
• Importance and difficulty of morphological diagnosis of MDS myelodysplastic syndromes (MDS) are acquired hematopoietic stem cell disorders characterized by therapy-resistant (refractory) cytopenia and preleukemic states. In addition to the risk of transformation to acute myeloid leukemia (AML) due to the increase in immature myeloid cells, most patients suffer from the bone marrow failure (BMF) as a result of severe cytopenia.
For the diagnosis of MDS, it is essential to confirm cytopenia and dysplastic morphology of blood cells. Bone marrow represents F I G U R E 4 An example of the photo panels uploaded in JSLH website for visual standardization. They are composed of not only typical cells but also ambiguous cells whose judgment would be controversial even among expert hematologists. The percentage written at the right-lower side of each photograph indicates the proportion of 11 experts who considered the cell as a myeloblast; 100% implies that the opinion of all the 11 experts completely coincided, while the cells lined around the lower side had a tendency to be judged as another cell such as a proerythroblast hypercellularity in general, but about 15% of MDS cases present hypocellular marrow (hypoplastic MDS) that is rather difficult to be distinguished from aplastic anemia. 6 Dysplastic morphology is not always specific in MDS. Therefore, it is necessary for us to consider any possible factors triggering dysplasia other than MDS and also to exclude them in order to raise the abnormal morphology correctly as the evidence for diagnosis of MDS.
It is noted in the WHO Blue Book (revised 4th edition, 2017 7 ) that the recommended requisite percentage of the dysplastic cells to consider as "significant" is more than 10 percent. The cases lacking in definite dysplasia may be denominated "minimal dysplasia," but this clinical entity is not settled. On the contrary, in the case of dysmegakaryopoiesis, some experts insist that "significant" dysmegakaryopoiesis needs more than 10% dysplastic megakaryocytes up to 30% or 40% of the lineage. 8 In addition, according to the revised International Prognostic Scoring System (IPSS-R), the accurate counting of blast percentage is also a critical point on the subclassification, risk assessment, and treatment strategy (less or more than 2% blast percentage will be important for risk assessment). has been conducting the prospective registration, central review, and follow-up study for aplastic anemia and MDS. 10, 11 Newly diagnosed patients with aplastic anemia or low-risk MDS have been enrolled in this prospective registration system, together with cytopenic cases with unknown etiologies. Enrolled patients whose bone marrow blasts were evaluated less than 5% at the institution where the patients visited (local evaluation) are subjected to our central review for final diagnosis.
Our proposed step for laboratory diagnosis of MDS is as follows: present, this prospective study will provide new evidence for the accuracy of our diagnostic system and the whole aspects of MDS in Japan.
| CON CLUS I ON AND PER S PEC TIVE S
Since its launching in 2000, JSLH has been steadily developed and the occasion of discussion around laboratory hematology has been extensively broadened. In the field of blood cell morphology, another independent organization, the Japanese National Research Group on BMF has raised the importance of the dysplasia of MDS and has been conducting the prospective registration, central review, and follow-up study of MDS. The author (KT) belongs to both organizations as an active member and is connecting them each other.
Japanese Society for Laboratory Hematology recently approved the grading system for diagnostic accuracy of MDS and adopted this diagnostic system to the educational item of the laboratory hematology specialists, aiming at a nationwidely expanding morphological evaluation of myelodysplasia.
Further and significant progress in the standardization of blood cell morphology will be expected in Japan through the activity of JSLH.
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